drugset / Trial / NCT02796183
The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.
Timeline
- Start
- 2015-01
- Primary completion
- 2016-04
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 3.75 mg | Other |